Searchable abstracts of presentations at key conferences in endocrinology

ea0064010 | Effect of nationwide reimbursement of sensor-augmented pump therapy in a paediatric type 1 diabetes population on HBA1C, hypoglycaemia and quality of life: the rescue-paediatrics study | BES2019

Effect of nationwide reimbursement of sensor-augmented pump therapy in a paediatric type 1 diabetes population on HBA1C, hypoglycaemia and quality of life: The rescue-paediatrics study

De Ridder F , Charleer S , Jacobs S , Casteels K , Van Aken S , Vanbesien J , Gies I , Massa G , Lysy P , Logghe K , Lebrethon M-C , Depoorter S , Ledeganck K , Gillard P , De Block C , den Brinker M

Background: Long-term real-life data of sensor-augmented pump therapy (SAP) in paediatric type 1 diabetes (T1D) patients are lacking.Objectives: To assess the impact of SAP in a nationwide study of paediatric T1D patients on HbA1c, hypoglycaemia and quality of life until 24 months.Methods: Between December 2014 an...

ea0071012 | Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: sub study of the RESCUE-trial | BES2020

Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: sub study of the RESCUE-trial

A El Malahi , M Van Elsen , S Charleer , F De Ridder , K Ledeganck , B Keymeulen , L Crenier , R Radermecker , B Lapauw , C Vercammen , F Nobels , C Mathieu , P Gillard , C De Block

Background and aims: So far, HbA1c is the only metric of glucose control showing a strong association with chronic complications. However, it does not reflect short-term glycemic variability nor provides guidance in decreasing risk of hypoglycemia. More widespread use of continuous glucose monitoring (CGM) has changed the way people with type 1 diabetes (T1D) manage their glycemia by providing information about glycemic variability and time spent in different glucose ranges.</...